Biocon Limited Announces Leadership Changes
Biocon Limited announced several leadership changes following a board meeting held on March 27, 2026. The changes include resignations and appointments impacting key executive positions within the company.Mr. Siddharth Mittal resigned from his position as Chief Executive Officer and Managing Director, effective March 31, 2026, to transition to another leadership role within the Biocon Group. Mr. Mukesh Kamath also resigned as Interim Chief Financial Officer, also effective March 31, 2026, to take up another role within the Biocon Group.
Mr. Shreehas Pradeep Tambe, currently Chief Executive Officer and Managing Director of Biocon Biologics Limited (BBL), has been appointed as the Additional Director of Biocon Limited, effective April 1, 2026, and as Chief Executive Officer and Managing Director (Key Managerial Personnel) for a period of 5 years, also effective April 1, 2026, subject to shareholder approval. Mr. Kedar Narayan Upadhye, currently Chief Financial Officer of BBL, will assume the role of Chief Financial Officer at Biocon Limited, effective April 1, 2026. Mr. Akhilesh Nand, Company Secretary of BBL, will be designated as the Head, Governance, Risk, and Compliance of Biocon Limited, effective April 1, 2026.
Additional senior management personnel appointments include Mr. Naveen Narayanan, Head, Global Head of HR of BBL, as Chief Human Resources Officer, and Mr. Mandar Shrikant Ghatnekar, Global Head of IT & Digital Transformation of BBL, as Chief Technology Officer, both effective April 1, 2026. Several senior management personnel, including Abhijit Zutshi, Manoj Kumar Pananchukunnath, Arun Kumar Gupta, Maninder Kapoor Puri, Nitin Tiwari, Vishal Nayyar, and Amit Kaptain, will cease to hold their current positions effective March 31, 2026.
The Board authorized Ms. Kiran Mazumdar-Shaw, Mr. Shreehas Pradeep Tambe, Mr. Kedar Narayan Upadhye, Mr. Akhilesh Nand, and Mr. Rajesh U. Shanoy to determine the materiality of events and make disclosures to stock exchanges.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.